OBO ID: CHEBI:47458

Term Name:	saracatinib		Search Ontology:
Synonyms:	AZ-10353926 AZD 0530 AZD-0530 AZD0530 N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine N-(5-chloro-2H-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-[(oxan-4-yl)oxy]quinazolin-4-amine saracatinib saracatinibum
Definition:	A member of the class of quinazolines that is quinazoline substituted by (5-chloro-2H-1,3-benzodioxol-4-yl)amino, (oxan-4-yl)oxy and 2-(4-methylpiperazin-1-yl)ethoxy groups at positions 4, 5 and 7, respectively. It is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively). Saracatinib was originally developed by AstraZeneca for the treatment of cancer but in 2019 it was granted orphan drug designation by the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs.
References:	CAS:379231-04-6 Chemspider:8477917 DrugBank:DB11805 KEGG:D09664 LINCS:LSM-1032 PDBeChem:H8H PMID:17064066 PMID:22452946 PMID:23151808 PMID:24111605 PMID:26009269 PMID:26062928 PMID:26474384 PMID:27135311 PMID:28396832 PMID:28792760 PMID:29435137 PMID:29614307 PMID:29795047 PMID:30536923 PMID:31329216 PMID:31485668 PMID:31667062 PMID:31801023 PMID:31931755 PMID:32051399 PMID:32397949 PMID:32398945 PMID:32635977 PMID:32686156 PMID:32692785 PMID:33410098 PMID:33451301 PMID:33603165 PMID:33705358 PMID:33910400 PMID:34087381 PMID:34158343 Wikipedia:Saracatinib
Ontology:	ChEBI  ( EBI )